Acalabrutinib - Acerta Pharma

Drug Profile

Acalabrutinib - Acerta Pharma

Alternative Names: ACP-196; CALQUENCE

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Acerta Pharma
  • Developer Acerta Pharma; AstraZeneca; Merck Sharp & Dohme; University Hospital Southampton NHS Foundation Trust
  • Class Antineoplastics; Benzamides; Heavy metals; Imidazoles; Pyrazines; Pyridines; Pyrrolidines; Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mantle-cell lymphoma; Waldenstrom's macroglobulinaemia; Chronic lymphocytic leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Mantle-cell lymphoma
  • Phase III Chronic lymphocytic leukaemia
  • Phase II Bladder cancer; Head and neck cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Rheumatoid arthritis; Waldenstrom's macroglobulinaemia
  • Phase I/II B cell lymphoma; B cell prolymphocytic leukaemia; Diffuse large B cell lymphoma; Glioblastoma; Multiple myeloma
  • No development reported Follicular lymphoma

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Chronic-lymphocytic-leukaemia(Combination therapy, Second-line therapy or greater) in USA (PO, Capsule)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Diffuse large B cell lymphoma(Second-line therapy or greater) in United Kingdom (PO, Capsule)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Diffuse large B cell lymphoma(Second-line therapy or greater) in USA (PO, Capsule)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top